XML 60 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions - Narrative (Details) - USD ($)
$ in Thousands
4 Months Ended 12 Months Ended
Oct. 25, 2019
Aug. 23, 2018
Apr. 20, 2017
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]              
Research and development         $ 257,452 $ 171,984 $ 117,456
Contingent consideration payable       $ 310,240 $ 356,300 310,240  
Issuance of common stock related to acquisition           155,860 75,191
Useful life         7 years    
BioElectron              
Finite-Lived Intangible Assets [Line Items]              
Payments for asset acquisitions $ 10,000            
Loan advance 4,000            
Escrow deposit disbursements related to property acquisition 1,500            
Research and development         $ 10,000    
Acquisition costs 500            
Acquisition Costs, Cumulative         10,500    
Cash consideration 10,000            
Development milestone payment obligations         200,000    
Intellectual Property | Marathon Pharmaceuticals, LLC              
Finite-Lived Intangible Assets [Line Items]              
Payments for asset acquisitions     $ 75,000        
Acquisition costs     $ (2,163)        
Issuance of common stock related to acquisition (in shares)     6,683,598        
Issuance of common stock related to acquisition     $ 75,190        
Useful life     7 years        
Non-collaborative Arrangement Transactions | Marathon Pharmaceuticals, LLC              
Finite-Lived Intangible Assets [Line Items]              
Cash consideration     $ 75,000        
Numerator for calculation of number of shares of equity interests issued to acquire entity     $ 65,000        
Trading day period     15 days        
Development milestone payment obligations     $ 50,000        
Agilis              
Finite-Lived Intangible Assets [Line Items]              
Cash consideration   $ 49,221          
Numerator for calculation of number of shares of equity interests issued to acquire entity   $ 150,000          
Trading day period   10 days          
Fair value of PTC common stock issued   $ 155,860          
Development milestone payment obligations   40,000     40,000    
Estimated fair value of contingent consideration payable   290,500          
Estimated fair value of deferred consideration payable   38,100          
Total consideration   533,681          
Estimated fair value of contingent consideration payable           1,700  
Loss of acquire since acquisition date       $ 8,700      
Net loss attributable to common stockholders           (138,083) $ (93,333)
Agilis | Non-collaborative Arrangement Transactions              
Finite-Lived Intangible Assets [Line Items]              
Development milestone payment obligations   $ 40,000     40,000    
Acquisition-related Costs | Agilis              
Finite-Lived Intangible Assets [Line Items]              
Net loss attributable to common stockholders           $ 1,700  
Maximum | BioElectron              
Finite-Lived Intangible Assets [Line Items]              
Net sales milestones $ 200,000            
Maximum | Agilis              
Finite-Lived Intangible Assets [Line Items]              
Net sales milestones         $ 150,000    
Percentage of annual net sales         6.00%    
Development milestone payment obligations         $ 60,000    
Priority review voucher amount         $ 535,000    
Minimum | Agilis              
Finite-Lived Intangible Assets [Line Items]              
Percentage of annual net sales         2.00%    
Common stock              
Finite-Lived Intangible Assets [Line Items]              
Issuance of common stock related to acquisition (in shares)           3,500,907 6,683,598
Issuance of common stock related to acquisition           $ 3 $ 7